Navigation Links
Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

roved lung function as measured by Forced Expiratory Volume in one second (FEV1) area under the curve from time zero to 24 hours post dose. Multiple secondary physiological (lung function) and pharmacokinetic endpoints will also be evaluated. Top-line results are expected in early 2014 and will form the basis of the future clinical development of PSX1002. For more information, see

Notes for Editors

About Prosonix

Prosonix is an innovative speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design.

Prosonix' ultrasonic particle engineering technology enables it to design and engineer mono and combination drug particles that precisely meet the specific requirements for inhalation, delivering assured formulation performance using simple, cost-effective devices for a range of generic, super-generic and novel products.

Prosonix' pipeline focuses on near- and long-term opportunities, including:

  • PSX1001/PSX1050, a directly substitutable generic version of fluticasone propionate, a potent inhaled corticosteroid (ICS) indicated for asthma and chronic obstructive pulmonary disease (COPD), in a pressurised metered dose inhaler (pMDI)
  • PSX2005, a directly substitutable generic version of a leading ICS/long-acting beta 2 agonist (LABA) combination in development for asthma and COPD in pMDI,
  • PSX1002, a drug-only proprietary formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA) indicated for COPD, in pMDI, and
  • PSX2000 MCP™ Series, novel combination medicines designed specifically for respiratory diseases and based on Multi-component Particles™.

Prosonix has raised more than £22 million from experienced life sciences investors including Ventech, Gi

SOURCE Prosonix
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
2. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
3. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
4. Applied Genetics Initiates Commercial Operation
5. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
6. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
9. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
10. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
11. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Post Your Comments:
(Date:10/8/2015)... October 8, 2015 ... --> Goldman Small Cap Research, a ... cap and microcap sectors, announced today that it ... PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly ... and preparing treatments for cancer and diabetes. To ...
(Date:10/8/2015)... , Oct. 8, 2015  The ALS Association, ... ALS Assistive Technology Challenge to revolutionize communication technology solutions ... --> ALS (amyotrophic lateral sclerosis) is ... in the brain and the spinal cord. Eventually, people ... muscle movement, which often leads to total paralysis and ...
(Date:10/8/2015)... ... October 08, 2015 , ... Talon Innovations, a provider ... and other technology-driven industries, announces that it is one of three finalists for the ... Company.” On Thursday, September 25 Talon Innovations was recognized as a nominee for ...
(Date:10/7/2015)... Mass. , Oct. 7, 2015 ... announced the start of the Boston Scientific Connected ... encourage advancements in the use of remote patient monitoring ... engineers, designers and entrepreneurs can submit their ideas and ... site ( ). Cambridge, MA ...
Breaking Biology Technology:
... Dec. 9 The results of a new study on ... 30 sites around the country, will be published in the ... Salloway, MD, MS, director of the Butler Hospital Memory and ... the Warren Alpert Medical School of Brown University, says that ...
... , SAN DIEGO, Dec. 9 ... life-saving medicines specifically designed to enhance the perfusion and ... and other gas delivery, today announced that the European ... MP4CO for the treatment of sickle cell disease. This ...
... ... Platform for High Throughput and High Content Screening. , ... Basel, Switzerland and Granada, Spain (PRWEB) December 8, ... discovery and life science research, and Fundación MEDINA (Centro de Excelencia en ...
Cached Biology Technology:
(Date:9/28/2015)... -- According to a new market research ... & Others), Application (Access Control & Others), Industry (Travel ... Global - Forecast to 2020", published by MarketsandMarkets, the Iris ... by 2020, at a CAGR of 23.40% between 2015 ... T ables and 66 Figures spread ...
(Date:9/24/2015)...  EyeLock LLC, a market leader of iris-based identity ... latest technology in Booth #602 at next week,s ASIS ... EyeLock,s iris authentication technology provides an unprecedented level ... it the most proven way to authenticate one,s identity ... deliver a fast and friendly user experience to identify ...
(Date:9/10/2015)... , Sept. 10, 2015 Report ... New Study Reveals Selling Opportunities and Revenue Prospects ... the future of biologics, especially new drug classes? ... will stay ahead with exclusive market data and ... explore trends, developments, results, opportunities and sales predictions. ...
Breaking Biology News(10 mins):
... event in reproductive medicine, is only weeks away - and ... one of the best sources of news and features in ... in London from 7-10th July. More than 9000 of ... and, from a total of 1600 abstracts of new research ...
... United States bring new insights to our understanding of the ... currently facing the fields of genomics and genetics. Their findings ... Roughly 3 metres of DNA is tightly folded into the ... some genes to be ,expressed, or activated, while excluding others. ...
... SAN DIEGO (June 23, 2013) A major study ... provides new revelations about the intricate pathways involved in turning on ... today in the prestigious scientific journal Nature . ... that a certain type of protein, called septins, play a critical ...
Cached Biology News:
... The Caliper Sciclone ALH 3000 workstation automates ... applications, from Genomic and Proteomic Sample Preparation ... The modular design of the Caliper ... and accessories to perfectly meet the needs ...
Designed for use with the Agencourt SprintPrep 384 kit and all MCPrep reagent kits. Used with flat bottom 96-well microplates such as deep well plates used to culture bacteria....
... TRAC is a platform for fully ... applications. It can easily be configured for ... to molecular biology.TRAC allows closed loop screening, ... screen, hit list generating, cherry picking and ...
... are disposable microfiltration devices for the fast and ... 100 l to 500 l. They can be ... centrifuge tubes. Product Features: High-flux Polyethersulphonemembrane ... Low hold up volume ( Fast and reproducible ...
Biology Products: